- Home
- TCRX vs PAAI Comparison
TCRX vs PAAI Comparison
Compare TCRX & PAAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$0.31
N/A
Current Price
$1.81
Company Overview
Basic Information| Metric | TCRX | PAAI |
|---|---|---|
| Founded | 2018 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.4M | 49.5M |
| IPO Year | 2021 | 2017 |
Fundamental Metrics
Financial Performance| Metric | TCRX | PAAI |
|---|---|---|
| Price | $0.31 | $1.81 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | 1.1M | ★ 4.1M |
| Earning Date | 05-08-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | 12.28 | ★ 191.93 |
| EPS | N/A | ★ N/A |
| Revenue | $10,325,000.00 | ★ $16,892,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $19.81 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 266.65 | 27.46 |
| 52 Week Low | $0.29 | $0.87 |
| 52 Week High | $2.57 | $3.47 |
Technical Indicators
Market Signals| Indicator | TCRX | PAAI |
|---|---|---|
| Relative Strength Index (RSI) | 21.36 | 58.99 |
| Support Level | N/A | $0.87 |
| Resistance Level | $0.82 | N/A |
| Average True Range (ATR) | 0.05 | 0.54 |
| MACD | -0.01 | 0.13 |
| Stochastic Oscillator | 4.94 | 34.80 |
Price Performance
Historical Comparison TCRX
PAAI
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.